Lupeol inhibits proliferation of human prostate cancer cells by targeting β-catenin signaling

Carcinogenesis

Volumn 30, Issue 5, 2009, Pages 808-817

  Saleem, Mohammad ^a   Murtaza, Imtiyaz ^a   Tarapore, Rohinton S ^a   Suh, Yewseok ^a   Adhami, Vaqar Mustafa ^a   Johnson, Jeremy James ^a   Siddiqui, Imtiaz Ahmad ^a   Khan, Naghma ^a   Asim, Mohammad ^a   Hafeez, Bilal Bin ^a   Shekhani, Mohammed Talha ^a   Li, Benyi ^b   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANGIOTENSIN 2 RECEPTOR; AXIN; BETA ACTIN; BETA CATENIN; CD82 ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; LUPEOL; MITOGEN ACTIVATED PROTEIN KINASE 12; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR 4; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C RECEPTOR; T CELL FACTOR PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRITERPENE;

ARTICLE; CANCER CELL; CARCINOGENICITY; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN STABILITY; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANTI-INFLAMMATORY AGENTS; BETA CATENIN; CELL DIVISION; CYCLIN D1; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRITERPENES;

EID: 65449167684     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp044     Document Type: Article

References (45)

1. Syed,D.N. et al. (2007) Chemoprevention of prostate cancer through dietary agents: Progress and promise. Cancer Epidemiol. Biomarkers Prev., 16, 2193-2203.
2. Klein,E.A. (2006) Chemoprevention of prostate cancer. Annu. Rev. Med. 57, 49-63.
3. Bettuzzi,S. et al. (2006) Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res., 66, 1234-1240.
4. Jian,L. et al. (2004) Protective effect of green tea against prostate cancer: A case-control study in southeast China. Int. J. Cancer., 108, 130-135.
5. Saleem,M. et al. (2005) A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res., 65 11203-11213.
6. Lee,T.K. et al. (2007) Lupeol suppresses cisplatin-induced nuclear factorkappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res., 67, 8800-8809.
7. Qin,H. et al. (1999) The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J. Biol. Chem., 274, 29130-29137.
8. Kyprianou,N. et al. (2000) Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res., 60, 4550-4555.
9. Karan,D. et al. (2003) Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int. J. Oncol., 23, 1365-1371.
10. Sidiropoulos,M. et al. (2005) Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol., 26, 324-336.
11. Koike,H. et al. (2005) Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: Implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer. Br. J. Cancer., 92, 1538-1544.
12. Krueckl,S.L. et al. (2004) Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res., 64, 8620-8629.
13. Meinbach,D.S. et al. (2006) Insulin-like growth factors and their binding proteins in prostate cancer: Cause or consequence? Urol. Oncol., 24, 294-306.
14. Hojilla,C.V. et al. (2007) Metalloproteinase axes increase beta-catenin signaling in primary mouse mammary epithelial cells lacking TIMP3. J. Cell Sci., 120, 1050-1060.
15. de la Taille,A. et al. (2003) Beta-catenin-related anomalies in apoptosisresistant and hormone-refractory prostate cancer cells. Clin. Cancer Res., 9, 1801-1807.
16. Verras,M. et al. (2006) Roles and regulation of Wnt signaling and betacatenin in prostate cancer. Cancer Lett., 237, 22-32.
17. Playford,M.P. et al. (2000) Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc. Natl Acad. Sci. USA., 97, 12103-12108.
18. Casimiro,M. et al. (2007) ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res., 67, 4364-4372.
19. Yardy,G.W. et al. (2005) Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis., 8, 119-126.
20. Henderson,B.R. et al. (2002) The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep., 3, 834-839.
21. Novak,A. et al. (1999) Signaling through beta-catenin and Lef/Tcf. Cell. Mol. Life Sci., 56, 523-537.
22. Chen,G. et al. (2004) Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer, 101 1345-1356.
23. Manoukian,A.S. et al. (2002) Role of glycogen synthase kinase-3 in cancer: Regulation by Wnts and other signaling pathways. Adv. Cancer Res., 84, 203-229.
24. Terry,S. et al. (2006) Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J. Cell. Biochem., 99, 402-410.
25. Liao,X. et al. (2004) Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology, 145, 2941-2949.
26. Cronauer,M.V. et al. (2005) Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int. J. Oncol., 26, 1033-1040.
27. Tetsu,O. et al. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398, 422-426.
28. Chesire,D.R. et al. (2003) Beta-catenin signaling in prostate cancer: An early perspective. Endocr. Relat. Cancer., 10, 537-560.
29. Yang,G. et al. (2005) Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer, 103, 1186-1194.
30. Kanoh,Y. et al. (2002) Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res., 22, 1813-1817.
31. Revelos,K. et al. (2007) Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res., 27, 3651-3660.
32. McCarty,M.F. (2004) Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy. Integr. Cancer Ther., 3, 349-380.
33. Wu,J.D. et al. (2006) Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 99, 392-401.
34. Di Lorenzo,G. et al. (2004) HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori, 90, 163-170.
35. Saleem,M. et al. (2005) Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. Carcinogenesis, 26, 1956-1964.
36. Saleem,M. et al. (2004) Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene, 23 5203-5214.
37. Saleem,M. et al. (2008) Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin. Cancer Res., 14, 2119-2127.
38. Ho,E. et al. (2004) Dietary influences on endocrine-inflammatory interactions in prostate cancer development. Arch. Biochem. Biophys. 428, 109-117.
39. Gross,M.E. et al. (2004) Update on HER-kinase-directed therapy in prostate cancer. Clin. Adv. Hematol. Oncol., 2, 53-56.
40. Ratan,H.L. et al. (2003) ErbB receptors: Possible therapeutic targets in prostate cancer? BJU Int., 92, 890-895.
41. Verras,M. et al. (2005) Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol. Endocrinol., 19, 391-398.
42. Morali,O.G. et al. (2001) IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene, 20, 4942-4950.
43. Zumkeller,W. (2001) IGFs and IGFBPs: Surrogate markers for diagnosis and surveillance of tumour growth? Mol. Pathol., 54, 285-288.
44. Knoepfler,P.S. (2007) Myc goes global: New tricks for an old oncogene. Cancer Res., 67, 5061-5063.
45. Chesire,D.R. et al. (2000) Detection and analysis of beta-catenin mutations in prostate cancer. Prostate, 45, 323-334.